liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy
College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates; Pharmacology, Clinical Biochemistry and Molecular Biology Units, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Pharmacology, Clinical Biochemistry and Molecular Biology Units, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Cancer Biology & Therapy, ISSN 1538-4047, E-ISSN 1555-8576, Vol. 16, nr 7, s. 1056-1070Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Lung cancer cells show inherent and acquired resistance to chemotherapy. The lack of good predictive markers/novel targets and the incomplete understanding of the mechanisms of resistance limit the success of lung cancer response to chemotherapy. In the present study, we used an isogenic pair of lung adenocarcinoma cell lines; A549 (wild-type) and A549DOX11 (doxorubicin resistant) to study the role of epigenetics and miRNA in resistance/response of non-small cell lung cancer (NSCLC) cells to doxorubicin. Our results demonstrate differential expression of epigenetic markers whereby the level of HDACs 1, 2, 3 and4, DNA methyltransferase, acetylated H2B and acetylated H3 were lower in A549DOX11 compared to A549 cells. Fourteen miRNAs were dys-regulated in A549DOX11 cells compared to A549 cells, of these 14 miRNAs, 4 (has-mir-1973, 494, 4286 and 29b-3p) have shown 2.99 – 4.44 fold increase in their expression. This was associated with reduced apoptosis and higher resistance of A549DOX11cells to doxorubicin and etoposide. Sequential treatment with the epigenetic modifiers trichostatin A or 5-aza-2'-deoxycytidine followed by doxorubicin resulted in: (i) enhanced sensitivity of both cell lines to doxorubicin especially at low concentrations, (ii) enhanced doxorubicin-induced DNA damage in both cell lines, (iii) dysregulation of some miRNAs in A549 cells. In conclusion, A549DOX11 cells resistant to DNA damaging drugs have epigenetic profile and miRNA expression different from the sensitive cells. Moreover, epigenetic modifiers may reverse the resistance of certain NSCLC cells to DNA damaging agents by enhancing induction of DNA damage. This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity.

Ort, förlag, år, upplaga, sidor
Philadelphia, PA, United States: Taylor & Francis, 2015. Vol. 16, nr 7, s. 1056-1070
Nyckelord [en]
doxorubicin; epigenetics; HDAC; miRNA; trichostatin A; 5-aza-20 -deoxycytidine
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:liu:diva-184474DOI: 10.1080/15384047.2015.1046023ISI: 000357699300008PubMedID: 25962089Scopus ID: 2-s2.0-84943743134OAI: oai:DiVA.org:liu-184474DiVA, id: diva2:1653576
Anmärkning

Funding: This work was supported by the KEF-HOLDING-FAIZAL and Shabana Foundation and the Boehringer Ingelheim Pharmaceutical company.

Tillgänglig från: 2022-04-22 Skapad: 2022-04-22 Senast uppdaterad: 2022-04-28Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Person

El-Serafi, Ahmed Taher

Sök vidare i DiVA

Av författaren/redaktören
El-Serafi, Ahmed Taher
I samma tidskrift
Cancer Biology & Therapy
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 8 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf